Gordon Research Conferences
PI_Conferences PI_Conferences_Past
Conference Program
 
Tuberculosis Drug Development
(This meeting is currently known as "Tuberculosis Drug Discovery & Development")
July 21-26, 2013
Renaissance Tuscany Il Ciocco Resort
Lucca (Barga), Italy

Related Meeting Information
The Tuberculosis Drug Development Gordon Research Conference was held in conjunction with the Tuberculosis Drug Development Gordon-Kenan Research Seminar. Please refer to the Tuberculosis Drug Development GKRS web page for more information.

The 2013 Gordon Conference on Tuberculosis Drug Development will cover the range of activities involved in discovering and producing new antibiotics to combat tuberculosis. The conference will feature discussions of target and compound discovery, new potential anti-TB compounds in development, clinical trial design and early trial results. We invite researchers interested in all aspects of drug development and welcome participants from academia, industry, government and non-governmental organizations. In particular, we invite trainees and scientists from TB-endemic countries to apply as their contribution to the struggle against TB is especially important. All participants are asked to submit abstracts of their work for presentation as posters, and some abstracts will be chosen for oral presentations. The conference provides the opportunity to interact with colleagues in an informal and intimate atmosphere and is designed to promote extensive discussion.


Contributors

SUNDAY
4:00 pm - 8:00 pmArrival and Check-in
6:00 pmDinner
7:30 pm - 7:40 pmWelcome / Introductory Comments by GRC Site Staff
7:40 pm - 8:50 pmThe Changing Landscape of TB Treatment
Discussion Leader: David Sherman (Seattle Biomedical Research Institute)
7:40 pm - 8:30 pm Koen Andries (Tibotec)
"Discovery and Development of Bedaquiline: A Rocky Road"
8:30 pm - 8:50 pm Discussion
MONDAY
7:30 am - 8:30 amBreakfast
9:00 am - 12:30 pmBiology: insights, targets and tools
Discussion Leader: Chris Sassetti (University of Massachusetts)
9:00 am - 9:25 am Kim Lewis (Northeastern University)
"Persisters: approaches to eradicate specialized survivor cells"
9:25 am - 9:35 am Discussion
9:35 am - 10:00 am Jyothi Rengarajan (Emory University School of Medicine)
"Targeting an M. tuberculosis immunomodulatory serine protease for adjunctive therapy"
10:00 am - 10:10 am Discussion
10:10 am Group Photo / Coffee Break
10:40 am - 11:05 am Dirk Schnappinger (Weill Cornell Medical College)
"Genetic approaches to facilitate TB drug development"
11:05 am - 11:15 am Discussion
11:15 am - 11:40 am Christoph Grundner (Seattle Biomedical Research Institute)
"Targeting a phosphoswitch of Mtb replication"
11:40 am - 11:50 am Discussion
11:50 am - 12:15 pm Sarah Fortune (Harvard School of Public Health)
"(Avoiding) resistance is futile"
12:15 pm - 12:30 pm Discussion
12:30 pmLunch
1:30 pm - 4:00 pmFree Time
4:00 pm - 5:30 pmPoster Session
5:30 pm - 7:30 pmTargets
Discussion Leader: Sabine Ehrt (Weill Cornell Medical College)
5:30 pm - 5:55 pm Luiz Pedro de Carvalho (MRC)
"Metabolomic applications for target engagement in antibiotic research"
5:55 pm - 6:10 pm Discussion
6:10 pm - 6:35 pm Omonike Olaleye (Texas Southern University)
"Methionine aminopeptidase as a potential chemotherapeutic target for tuberculosis"
6:35 pm - 6:45 pm Discussion
6:45 pm - 7:20 pm Stewart Cole (EPFL, École polytechnique fédérale de Lausanne)
"Promiscuous targets"
7:20 pm - 7:30 pm Discussion
8:00 pmDinner
TUESDAY
7:30 am - 8:30 amBreakfast
9:00 am - 12:30 pmScreening tools and approaches
Discussion Leader: Thomas Dick (National University of Singapore)
9:00 am - 9:25 am Tom Blundell (University of Cambridge)
"Understanding and targeting the Mtb proteome: the application of computational and fragment-based approaches"
9:25 am - 9:35 am Discussion
9:35 am - 10:00 am Ruben Tommasi (AstraZeneca)
"The search for novel antibacterials: a summary of AZ's screening and lead finding approaches, lessons learned and outlook for the future"
10:00 am - 10:10 am Discussion
10:10 am Coffee Break
10:40 am - 11:05 am Manfred Auer (University of Edinburgh)
"Chemical Systems Biology and Biophysics using Tagged One-Bead One-Compound Combinatorial Chemical Libraries"
11:05 am - 11:15 am Discussion
11:15 am - 11:40 am Joel Freundich (University of Medicine and Dentistry, New Jersey)
"Bayesian models for antitubercular drug discovery"
11:40 am - 11:50 am Discussion
11:50 am - 12:20 pm Tim Wells (Medicines for Malaria Venture)
"Drug discovery and development for malaria control and elimination"
12:20 pm - 12:30 pm Discussion
12:30 pmLunch
1:30 pm - 4:00 pmFree Time
4:00 pm - 5:30 pmPoster Session
5:30 pm - 7:30 pmTarget-based or phenotypic screening? You be the judge
Discussion Leader: Ken Duncan (Bill and Melinda Gates Foundation)
5:30 pm - 6:00 pm Courtney Aldrich (University of Minnesota School of Pharmacy)
"Targeting biotin metabolism in Mycobacterium tuberculosis"
6:00 pm - 6:10 pm Discussion
6:10 pm - 6:40 pm Brian Vanderven (Cornell University)
"Targeting the intracellular replication of M. tuberculosis for drug discovery"
6:40 pm - 6:50 pm Discussion
6:50 pm - 7:20 pm Tanya Parish (Infectious Disease Research Institute)
"Squaring the circle - using phenotypic screens to find targeted compounds?"
7:20 pm - 7:30 pm Discussion
8:00 pmDinner
WEDNESDAY
7:30 am - 8:30 amBreakfast
9:00 am - 12:30 pmCompounds
Discussion Leader: David Barros (GlaxoSmithKline)
9:00 am - 9:25 am Kelly Chibale (Institute of Infectious Disease and Molecular Medicine, S. Africa)
"Medicinal chemistry progression of phenotypic HTS hits for TB from SoftFocus libraries"
9:25 am - 9:35 am Discussion
9:35 am - 10:00 am Giovanna Poce (Sapienza Università di Roma)
"BM212-derived MmpL3 inhibitors enabling new possibilities for the treatment of TB"
10:00 am - 10:10 am Discussion
10:10 am Coffee Break
10:40 am - 11:10 am Michael Shultz (Novartis)
"Optimization of binding enthalpy using lipophilic efficiency"
11:10 am - 11:20 am Discussion
11:20 am - 11:50 am Marvin Miller (University of Notre Dame)
"Syntheses and evaluation of new anti-tuberculosis agents Inspired by studies of mycobacterial iron assimilation"
11:50 am - 12:00 pm Discussion
12:00 pm - 12:15 pm Anil Koul (Janssen Research and Development, Johnson and Johnson Pharmaceuticals)
"Delayed bactericidal response to bedaquiline involves extensive remodeling of metabolic pathways in Mycobacterium tuberculosis"
12:15 pm - 12:30 pm Discussion
12:30 pmLunch
1:30 pm - 4:00 pmFree Time
4:00 pm - 5:30 pmPoster Session
5:30 pm - 7:30 pmEBA - what it does and doesn't measure
Discussion Leader: Paul van Helden (Stellenbosch University)
5:30 pm - 6:00 pm Andreas Diacon (Stellenbosch University)
"The EBA -- what it does and doesn't measure"
6:00 pm - 6:10 pm Discussion
6:10 pm - 6:40 pm Carol Nacy (Sequella)
"Developing new drugs for TB: do they all need to act like INH?"
6:40 pm - 6:50 pm Discussion
6:50 pm - 7:20 pm Bavesh Kana (University of Witwatersrand)
"Differential bacterial culturability in tuberculous sputum: Can we look at both sides of the same coin at once?"
7:20 pm - 7:30 pm Discussion
7:30 pm - 8:00 pmBusiness Meeting
Nominations for the next Vice Chair; Fill out Conference Evaluation Forms; Discuss future Site & Scheduling preferences; Election of the next Vice Chair
8:00 pmDinner
THURSDAY
7:30 am - 8:30 amBreakfast
9:00 am - 12:30 pmDrugs in humans and other animals
Discussion Leader: Gerry Davies (Liverpool School of Tropical Medicine)
9:00 am - 9:25 am Khisimuzi Mdluli (TB Alliance)
"Identifying novel treatment shortening regimens for DS/DR tuberculosis - from preclinical models to clinical trials"
9:25 am - 9:35 am Discussion
9:35 am - 10:00 am Eric Nueremberger (Johns Hopkins University)
"Animal efficacy models for TB drug development: trials and tribulations"
10:00 am - 10:10 am Discussion
10:10 am Coffee Break
10:40 am - 11:05 am Charles Peloquin (University of Florida)
"Accounting for Variability: Pharmacokinetics in TB Treatment"
11:05 am - 11:15 am Discussion
11:15 am - 11:40 am Brendan Prideaux (PHRI-Rutgers University)
"Assessing lesion-specific pharmacokinetics of tuberculosis drugs using mass spectrometry imaging"
11:40 am - 11:50 am Discussion
11:50 am - 12:15 pm Lalita Ramakrishan (University of Washington)
"Macrophage-induced bacterial efflux pumps as mediators of drug tolerance and virulence"
12:15 pm - 12:30 pm Discussion
12:30 pmLunch
1:30 pm - 4:00 pmFree Time
4:00 pm - 5:30 pmPoster Session
5:30 pm - 7:30 pmRegimens, trials and insights
Discussion Leader: Khisimuzi Mdluli (TB Alliance)
5:30 pm - 5:55 pm Nick Paton (NUHS)
"Trials of new treatment strategies for drug sensitive TB: challenges in design and implementation"
5:55 pm - 6:10 pm Discussion
6:10 pm - 6:35 pm Robert Wallis (Pfizer)
"Culture status at 2 months as a predictor of required treatment duration of new TB regimens"
6:35 pm - 6:45 pm Discussion
6:45 pm - 7:10 pm Clif Barry (National Institute of Allergy and Infectious Disease)
"The future of oxazolidinones in the treatment of TB"
7:10 pm - 7:20 pm Discussion
7:20 pm - 7:30 pm Meeting summary and wrap-up
8:00 pmDinner
FRIDAY
7:30 am - 8:30 amBreakfast
9:00 amDeparture

Funding for this conference was made possible [in part] by 1 R13 AI106046-01 from the National Institute of Allergy and Infectious Diseases. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

 
© 2014 Gordon Research Conferences Search | Contact | Terms of Use | Privacy Policy | Follow us: Facebook Twitter